title: [Tamoxifen and endometrial pathology].
abstract: Tamoxifen is a non-steroid antiestrogen, used as adjuvant therapy for breast carcinoma in women with positive estrogen receptor (ER+). In this report we evaluated endometrial histological changes in women treated with Tamoxifen for ER+ breast carcinoma.
  
  
  METHODS
  We performed transvaginal ultrasonography for the endometrial thickness and biopsy of endometrium on a group of 125 symptomatic women with Tamoxifen therapy for ER+ breast carcinoma. The endometrial specimens were histologically processed for histological diagnosis.
  
  
  RESULTS
  Of all patients, 49.6% had endometrial pathology (women with functional hemorrhage), and 32% had atrophic endometrium. Endometrial pathology was represented by endometrial simple hyperplasia 17.6%, and endometrial complex hyperplasia 8.8%. Endometrial complex hyperplasia with atypia was found in 5.6%, endometrial polyps in 11.2%, endometrial carcinoma in 4.8% and müllerian mixt tumor in 1.6%.
  
  
  CONCLUSIONS
  Endometrial pathology was more likely to be diagnosed in gynecological symptomatic postmenopausal and premenopausal women with breast carcinoma treated with Tamoxifen. Therefore, it is necessary that these patients to be supervise, first, with transvaginal ultrasonography for endometrium, and after, with biopsy of endometrium. All patients on long-term Tamoxifen therapy should be annually screened by endometrial biopsy for endometrial pathology.
authors.affiliation: Universităţii de Medicină si Farmacie Gr.T. Popa Iaşi.
authors.forename: M
authors.initials: M
authors.lastname: Negoiţă
authors.forename: C
authors.initials: C
authors.lastname: Terinte
authors.forename: Maria Sultana
authors.initials: MS
authors.lastname: Mihailovici
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001706:Biopsy; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology*; D004717:Endometrium / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology*; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000139:chemically induced / Q000473:pathology; D011127:Polyps / Q000139:chemically induced / Q000473:pathology; D011960:Receptors, Estrogen / Q000032:analysis; D012189:Retrospective Studies; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D014463:Ultrasonography; D014591:Uterine Diseases / Q000139:chemically induced / Q000473:pathology; D014594:Uterine Neoplasms / Q000139:chemically induced / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen